Table 2. (A) Clinico-pathological characteristics of patients (n=157); (B) Multivariate analysis of prognostic factors.
| Characterstic | Number of cases (frequency) | ||
|---|---|---|---|
| (A) | |||
| Grade 1 | 29 (0.19) | ||
| Grade 2 | 60 (0.39) | ||
| Grade 3 | 63 (0.41) | ||
| Missing | 5 | ||
| Stage 1 | 63 (0.41) | ||
| Stage 2 | 87 (0.56) | ||
| Stage 3 | 6 (0.03) | ||
| Missing | 2 | ||
| Node positive | 69 (0.45) | ||
| Node negative | 83 (0.55) | ||
| Missing | 5 | ||
| ER positive | 119 (0.76) | ||
| ER negative | 38 (0.24) | ||
| PgR positive | 84 (0.54) | ||
| PgR negative | 73 (0.46) | ||
| HER-2 positive | 19 (0.12) | ||
| HER-2 negative | 136 (0.88) | ||
| Missing | 2 | ||
| TP53 mutation | 46 (0.29) | ||
| TP53 wild-type | 111 (0.71) | ||
| NT5E methylated (ER positive) | 77 (0.65) | ||
| NT5E methylated (ER negative) | 19 (0.5) | ||
|
(B)
| |||
| Variable | Hazard ratio | P- value | 95% CI |
| Tumour grade | 1.548 | 0.002 | 1.168–2.052 |
| Nodal status | 1.099 | 0.000 | 1.043–1.160 |
| ER positive | 0.372 | 0.12 | 0.107–1.291 |
| PgR positive | 0.497 | 0.182 | 0.178–1.387 |
| TP53 mutation | 2.041 | 0.08 | 0.919–4.529 |
| NT5E methylation | 0.328 | 0.010 | 0.141–0.765 |